39.72

2.98% 1.15

After Hours: 39.47 -0.25 -0.63%

Rapport Therapeutics Inc (RAPP)

Overview News Price History Discussions Forecast

Rapport Therapeutics Inc stock is traded at $39.72, with a volume of 859.91K. It is up +2.98% in the last 24 hours and up +10.03% over the past month. Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Previous Close:

$38.57

Open:

$39.16

24h Volume:

859.91K

Relative Volume:

2.39

Market Cap:

$1.90B

Revenue:

Net Income/Loss:

$-107.28M

P/E Ratio:

-15.26

EPS:

-2.6031

Net Cash Flow:

$-80.71M

1W Performance:

-4.68%

1M Performance:

+10.03%

6M Performance:

+31.87%

1Y Performance:

+229.90%

1-Day Range:

$38.50

$42.86

1-Week Range:

$38.50

$42.86

52-Week Range:

$11.91

$43.76

Rapport Therapeutics Inc Stock (RAPP) Company Profile

Name

Rapport Therapeutics Inc

Sector

Healthcare (1094)

Industry

Biotechnology (615)

Phone

857-321-8020

Address

99 HIGH STREET, BOSTON

Employee

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

RAPP's Discussions on Twitter

Compare RAPP vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RAPP Rapport Therapeutics Inc	39.72	1.84B	0	-107.28M	-80.71M	-2.6031
VRTX Vertex Pharmaceuticals Inc	522.25	134.41B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	676.23	68.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.94	57.01B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	321.59	41.79B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	190.46	40.39B	742.00K	-1.37B	-1.07B	-7.0731

Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-10-26	Initiated	Raymond James	Strong Buy
Feb-02-26	Initiated	Wells Fargo	Overweight
Nov-19-25	Initiated	BTIG Research	Buy
Sep-16-25	Initiated	Truist	Buy
Aug-06-25	Initiated	H.C. Wainwright	Buy
Apr-08-25	Initiated	Citizens JMP	Mkt Outperform
Jul-02-24	Initiated	Jefferies	Buy
Jul-02-24	Initiated	Stifel	Buy
Jul-02-24	Initiated	TD Cowen	Buy

View All

Rapport Therapeutics Inc Stock (RAPP) Latest News

Jul 03, 2026

How Broad Russell Index Additions At Rapport Therapeutics (RAPP) Have Changed Its Investment Story - simplywall.st

Jul 03, 2026

Jul 02, 2026

Rapport Therapeutics (RAPP) COO sells 10,000 shares in pre-set 10b5-1 trades - Stock Titan

Jul 01, 2026

Rapport Therapeutics (RAPP) CEO sells 8,220 shares under Rule 10b5-1 plans - Stock Titan

Jul 01, 2026

Jun 30, 2026

[144] Rapport Therapeutics, Inc. SEC Filing - Stock Titan

Jun 30, 2026

Rapport Therapeutics stock hits all-time high at 42.36 USD By Investing.com - Investing.com Nigeria

Jun 30, 2026

Jun 29, 2026

Rapport Therapeutics, Inc.(NasdaqGM: RAPP) added to Russell 2500 Growth Benchmark - marketscreener.com

Jun 29, 2026

Rapport Therapeutics, Inc.(NasdaqGM:RAPP) added to Russell Microcap Growth Benchmark Index - marketscreener.com

Jun 29, 2026

Rapport Therapeutics, Inc.(NasdaqGM: RAPP) added to Russell 2000 Growth Benchmark - marketscreener.com

Jun 29, 2026

Rapport Therapeutics, Inc.(NasdaqGM: RAPP) added to Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Rapport Therapeutics, Inc.(NasdaqGM:RAPP) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com

Jun 28, 2026

Jun 26, 2026

Rapport Therapeutics, Inc. Actuals & Estimates (NASDAQ:RAPP) - TradingView

Jun 26, 2026

Jun 25, 2026

RAPP Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Jun 24, 2026

RAPP Initiated Coverage by Leerink Partners -- Rating set to Out - GuruFocus

Jun 24, 2026

Leerink Partners Initiates Rapport Therapeutics at Outperform With $52 Price Target - marketscreener.com

Jun 24, 2026

Leerink initiates Rapport Therapeutics stock with outperform rating By Investing.com - Investing.com Nigeria

Jun 24, 2026

Jun 23, 2026